<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3006210838
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DAVLEX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DESVENLAFAXINE SUCCINATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        74.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED INTERNATIONAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED INTERNATIONAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Davlex is used in the treatment and prevention of relapse of depression.</p><p>Depression can affect your whole body and may cause emotional and physical symptoms such as feeling low in spirit, being unable to enjoy life, poor appetite or overeating, disturbed sleep, loss of sex drive,</p><p>lack of energy and feeling guilty over nothing.</p><p>Ask your doctor if you have any questions about why Davlex has been prescribed for you Your doctor may have prescribed it for another reason.</p><p><strong>How it works</strong></p><p>Davlex contains the active ingredient called desvenlafaxine succinate. It belongs to a class of medications</p><p>called Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs).</p><p>Serotonin and noradrenaline are chemical messengers that allow certain nerves in the brain to work.</p><p>Davlex tablets increase the level of these two messengers. Experts think this is how it helps to restore your</p><p>feeling of wellness.</p><p>Davlex is not addictive. It is available only with a doctor&#39;s prescription.</p><p><strong>Use in Children</strong></p><p>The safety and effectiveness of Davlex in children or adolescents under 18 years of age have not been established</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take </strong><strong>Davlex </strong><strong>if you:</strong></p><p>&bull; Are taking other medications for depression known as monoamine</p><p>oxidase inhibitors, even if you have stopped taking them, but have</p><p>taken them within the last 14 days.</p><p>&bull; Have <strong>had allergic reactions </strong>desvenlafaxine, venlafaxine or to any of the</p><p>ingredients listed at the end of this leaflet.</p><p><strong>Symptoms of an allergic reaction include:</strong></p><p>&bull; Skin rash</p><p>&bull; Itching or hives on the skin</p><p>&bull; Swelling of the face, lips, tongue, throat or other parts of the body</p><p>&bull; Shortness of breath, wheezing,troubled breathing or difficulty swallowing.</p><p>&nbsp; Do not take this medicine after the expiry date (EXP) printed on the pack, or if the packaging is torn&nbsp;&nbsp; or shows signs of tampering.</p><p>&nbsp; If it has expired or is damaged, return it to your pharmacist for disposal.</p><p>&nbsp; If you are not sure whether you should start taking this medicine, talk to your doctor.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>Before take Davlex :</strong></p><p>Tell your doctor or pharmacist if you have allergies to any other medicines, foods, preservatives or</p><p>dyes.</p><p>Tell your doctor or pharmacist if you are pregnant or intend to become pregnant.</p><p>Davlex is not recommended for use during pregnancy. Your doctor will discuss the risks and benefits of</p><p>taking Davlex if you are pregnant.</p><p>One of these risks is that newborn babies whose mothers have been taking Davlex may have several</p><p>problems including breathing difficulties, rapid breathing, seizures, lack of oxygen in their blood,</p><p>physical and / or behavioural problems, vomiting and diarrhoea.</p><p>If you take Davlex or similar antidepressants mid to late in your pregnancy, you may develop a condition known as &quot;pre-eclampsia&quot;, which is characterised by persistent high-blood pressure during or after pregnancy. Symptoms of preeclampsia can include headaches, abdominal pain, shortness of breath</p><p>or burning behind the sternum, nausea and vomiting, confusion, heightened state of anxiety, and/or visual disturbances such as oversensitivity to light, blurred vision, or seeing flashing spots or auras.</p><p>If you take Davlex or similar antidepressants in the last month of your pregnancy, you may experience heavy bleeding during and/or after delivery.</p><p>Continuing treatment with Davlex or similar antidepressants during</p><p>pregnancy should be strictly as directed by your doctor.</p><p>Symptoms of a relapse may occur if treatment is discontinued, even if major depression was previously under control.</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you are breast-feeding or plan to breast-feed.</strong></p><p>Davlex passes into breast milk and there is a possibility that the breastfed baby may be affected. For this</p><p>reason, the use of Davlex is not recommended in breast-feeding women.</p><p>&nbsp;</p><p><strong>Tell your doctor if you have, or have had, any medical conditions, especially the following:</strong></p><p>&bull; A history of fits (seizures or convulsions)</p><p>&bull; A personal history or family history of bipolar disorder</p><p>&bull; Blood pressure problems</p><p>&bull; Glaucoma (increased pressure in the eye)</p><p>&bull; A tendency to bleed more than normal or you are taking a blood thinning medication</p><p>&bull; Raised cholesterol or lipid levels</p><p>&bull; Problems with your kidneys or liver</p><p>&bull; Problems with your heart</p><p>&bull; Low sodium levels in your blood</p><p>&bull; Any other medical conditions.</p><p><strong>Tell your doctor if you plan to have surgery.</strong></p><p>If you have not told your doctor about any of the above, tell them before you start to take Davlex.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Davlex</strong></p><p>Tell your doctor or pharmacist if you take any other medicines, including:</p><p>&bull; All prescription medicines</p><p>&bull; All medicines, vitamins, herbal supplements or natural therapies you buy without a prescription from a pharmacy, supermarket, naturopath or health food shop, such as St John&#39;s wort or tryptophan supplements.</p><p>Do not start to take any other medicine while you are taking</p><p>Davlex, unless it is prescribed or approved by your doctor.</p><p>Some medicines may interfere with Davlex or Davlex may interfere withthese medicines. These include:</p><p>&bull; Medications for depression known as monoamine oxidase inhibitors (MAOIs) (such as moclobemide, phenelzine and tranylcypromine). Tell your doctor if you are taking or have stopped taking them within the last 14 days. Ask your doctor or pharmacist if you are unsure if you are taking any of these medicines. It is important that you do not take Davlex or medicines similar to Davlex with MAOIs or within 14 days of taking an MAOI as this may result in a serious life-threatening condition. Your doctor or pharmacist can tell you what to do if you are taking any of these medicines.</p><p>&bull; Any other medications for bipolar disorder, depression, anxiety, obsessive-compulsive disorder or pre-menstrual dysphoric disorder, including St John&#39;s wort</p><p>&bull; Drugs that affect serotonin levels e.g. tramadol, dextromethorphan, fentanyl, methadone and pentazocine</p><p>&bull; Medicines used to treat Attention Deficit Hyperactivity Disorder (ADHD) such as</p><p>dexamphetamine and lisdexamphetamine</p><p>&bull; Medicines for weight loss, including sibutramine</p><p>&bull; Triptans (used to treat migraine)</p><p>&bull; Linezolid (used to treat infections)</p><p>&nbsp;&bull; Drugs that affect your tendency to bleed e.g. Aspirin, NSAIDS, Warfarin.</p><p>You may need to take different amounts of your medicine, or you may need to take different medicines.</p><p>Your doctor will advise you.</p><p>Your doctor or pharmacist has more in formation on medicines to be careful with or to avoid while taking Davlex.</p><p>&nbsp;</p><p><strong>Switching to Davlex from other antidepressants</strong></p><p>Side effects from discontinuing antidepressant medication may occur if you are switched from other antidepressants, including venlafaxine, to Davlex. Your doctor</p><p>may gradually reduce the dose of your initial antidepressant medication to help reduce these side effects.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Swallow the tablets whole with a glass of water or other nonalcoholic</p><p>liquid.</p><p>Do not divide, crush, chew or place the tablets in water.</p><p>Do not be concerned if you see a tablet &#39;shell&#39; in your faeces after taking Davlex.</p><p>As the tablet travels the length of your gastrointestinal tract, the active ingredient desvenlafaxine is slowly</p><p>released. The tablet &#39;shell&#39; remains undissolved and is eliminated in your faeces. Therefore, even though, you</p><p>may see a tablet &#39;shell&#39; in your faeces, your dose of desvenlafaxine has been absorbed.</p><p>&nbsp;</p><p><strong><em>How much to take</em></strong></p><p>The usual dose is 50 mg taken once daily with or without food.</p><p><strong>Do not change your dose unless your doctor tells you to.</strong></p><p>Your doctor will gradually increase your dose if needed.</p><p>If you have kidney problems, you may need a lower dose of Davlex.</p><p>&nbsp;</p><p><strong><em>When to take it</em></strong></p><p><strong>Take Davlex at approximately the same time each day.</strong></p><p>This could be either in the morning or in the evening.</p><p>Taking it at the same time each day will have the best effect. It will also help you remember when to take it.</p><p>&nbsp;</p><p><strong><em>How long to take it</em></strong></p><p><strong>Continue taking your medicine for as long as your doctor tells you.</strong></p><p>Although you may begin to feel better after two weeks, it may take several weeks before you feel much better. It is important to give Davlextime to work.</p><p>This medicine helps to control your condition, so it is important to keep taking your medicine even if you feel well.</p><p>&nbsp;</p><p><strong><em>If you forget to take it</em></strong></p><p>If it is less than 12 hours until your next dose, skip the dose you missed and then take your next dose when you are meant to. Otherwise, take it as soon as you remember, and then go back to taking as you would normally.</p><p>Do not take a double dose to make up for the dose you missed.</p><p>This may increase the chance of you getting an unwanted side effect.</p><p>If you are not sure what to do, ask your doctor or pharmacist.</p><p>If you have trouble remembering when to take your medicine, ask your pharmacist for some hints</p><p>&nbsp;</p><p><strong><em>If you take too much</em></strong></p><p><strong><em>(overdose)</em></strong></p><p>Immediately telephone your doctor or the Poisons Information Centre (telephone: 997) for advice, or go to Accident and Emergency at your nearest hospital if you think that you or anyone else may have taken too much Davlex.</p><p>Do this even if there are no signs of discomfort or poisoning.</p><p>You may need urgent medical attention.</p><p>Keep the telephone number for these places handy whilst taking any medications.</p><p>&nbsp;</p><p><strong>While you are taking</strong></p><p><strong>Davlex</strong></p><p><strong><em>Things you must do</em></strong></p><p><strong>Visit your doctor regularly for a check up so that your progress can be checked. Always discuss any</strong></p><p><strong>questions you have about Davlex with your doctor.</strong></p><p><strong>Take Davlex tablets as your doctor has prescribed.</strong></p><p><strong>Tell any other doctors, dentists and pharmacists who treat you that you are taking this medicine.</strong></p><p><strong>Keep enough Davlex tablets to last weekends and holidays.</strong></p><p>This medicine helps to control your condition, but does not cure it. It is important to keep taking your medicine even if you feel well.</p><p><strong>Watch carefully for signs that your depression is getting worse, especially in the first few weeks of treatment or if your dose has changed.</strong></p><p><strong>&nbsp;</strong></p><p>Sometimes people with depression can experience a worsening of their depressive symptoms. This can happen even when taking an antidepressant.</p><p>Tell your doctor there is the potential for a false positive urinary drug screen while on Davlex.</p><p><strong>Tell your doctor immediately if you experience any of the following symptoms, especially if they are severe, you have not had these symptoms before or they happen very suddenly.</strong></p><p>&bull; Anxiety or agitation</p><p>&bull; Panic attacks</p><p>&bull; Difficulty sleeping</p><p>&bull; Irritability</p><p>&bull; Aggressiveness</p><p>&bull; Hostility or impulsiveness</p><p>&bull; Restlessness</p><p>&bull; Overactivity or uninhibited behaviour</p><p>&bull; Other unusual changes in behaviour</p><p>&bull; Thoughts of suicide.</p><p><strong>Tell your doctor immediately if you have any thoughts about suicide or doing harm to yourself.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Warning signs of suicide:</em></strong></p><p><strong>If you or someone you know is showing the following warning signs, contact your doctor or a mental health advisor right away or go to the nearest hospital for treatment.</strong></p><p>All thoughts or talk about suicide or violence are serious.</p><p>&bull; Thoughts or talk about death or suicide</p><p>&bull; Thoughts or talk about self-harm or doing harm to others</p><p>&bull; Any recent attempts of self-harm</p><p>&bull; An increase in aggressive behaviour, irritability or agitation.</p><p>&nbsp;</p><p><strong><em>Things to be careful of</em></strong></p><p><strong>Be careful driving or operating dangerous machinery until you know how Davlex affects you.</strong></p><p>Davlex tablets may make you feel drowsy.</p><p>&nbsp;</p><p><strong><em>Things you must not do</em></strong></p><p><strong>Do not stop taking Davlex or change the dose without the advice of your doctor, even if you feel better.</strong></p><p>Your doctor may want to slowly decrease your dose of Davlex to help avoid side effects. Side effects are</p><p>known to occur when people stop taking Davlex, especially when they suddenly stop therapy.</p><p>Some of these side effects include:</p><p>&bull; Headache</p><p>&bull; Nausea</p><p>&bull; Dizziness</p><p>&bull; Tiredness</p><p>&bull; Irritability</p><p>&bull; Anxiety</p><p>&bull; Abnormal dreams</p><p>&bull; Diarrhoea</p><p>&bull; Excessive sweating</p><p>&bull; Visual impairment</p><p>&bull; High blood pressure</p><p>Slowly reducing the amount of Davlex being taken reduces the possibility of these effects occurring. In some people this may need to occur over periods of months or longer.</p><p>Some of these symptoms may impair driving, or the operation of dangerous machinery. Avoid these</p><p>activities if you experience any of these symptoms.</p><p>Avoid drinking alcohol while you are taking Davlex.</p><p>Do not give this medicine to anyone else even if they have the same condition as you.</p><p>&nbsp;</p><p>Palpitations, shortness of breath, intense chest pain, or irregular heartbeats</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking Davlex.</p><p>All medicines can have side effects.</p><p>Sometimes they are serious; often they are not. You may need medical attention if you get some of the side effects.</p><p>It can be difficult to tell whether side effects are the result of taking this medicine, symptoms of your condition, or side effects of other medicines you may be taking. For this reason it is important to tell your doctor of any change in your condition.</p><p>&nbsp;</p><p>Do not be alarmed by the list of side effects.</p><p>You may not experience any of them.</p><p>Ask your doctor or pharmacist to answer any questions you may have.</p><p>&nbsp;</p><p>Tell your doctor if...</p><p>Tell your doctor or pharmacist if you notice any of the following and they worry you:</p><p>&bull; Stomach, bowel or urinary tract problems:</p><p>- Nausea or vomiting</p><p>- Loss of appetite</p><p>- Diarrhoea</p><p>- Constipation</p><p>- Difficulty passing urine</p><p>&bull; Changes in your behaviour:</p><p>- Difficulty sleeping, abnormal sleepiness or abnormal dreams</p><p>- Sexual function problems such as decreased sex drive, delayed ejaculation, problems achieving erection or difficulties achieving orgasm</p><p>- Nervousness or anxiety</p><p>- Feeling jittery or irritable</p><p>&bull; Difficulty thinking or working because of:</p><p>- Yawning</p><p>- Disturbances in concentration</p><p>- Fainting or dizziness after standing up</p><p>- Fatigue</p><p>- Rapid heart beat</p><p>- Chills</p><p>- Headache</p><p>&bull; Excessive sweating</p><p>&bull; Hot flushes</p><p>&bull; Rash</p><p>&bull; Weight loss</p><p>&bull; Weight gain</p><p>&bull; Blurred vision</p><p>&bull; Ringing in the ears</p><p>&bull; Altered taste, dry mouth.</p><p>Tell your doctor as soon as possible</p><p>if you notice any of the following:</p><p>&bull; Muscle spasms, stiffness, weakness or movement disorders</p><p>&bull; Abnormal facial movements such as tongue thrusting, repetitive chewing, jaw swinging, or grimacing</p><p>&bull; A feeling of apathy or not caring about things</p><p>&bull; Feeling detached from yourself</p><p>&bull; Hallucinations</p><p>&bull; Confusion</p><p>&bull; Agitation</p><p>&bull; Unusually overactive</p><p>&bull; Problems with breathing, shortness of breath</p><p>&bull; Bleeding or bruising more easily than normal</p><p>&bull; Numbness or pins and needles</p><p>&bull; Sensitivity to sunlight.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Go to hospital if...</p><p>Tell your doctor immediately, or go to Accident and Emergency at your nearest hospital if you notice any of the following:</p><p>&bull; Severe upper abdominal pain</p><p>&bull; Swollen and tender abdomen</p><p>&bull; Fever</p><p>&bull; Rise or decrease in blood pressure. You may experience headache, blurred&nbsp; vision, palpitations, confusion or loss of consciousness. Sometimes you may not experience any of these symptoms. It is important to keep 0your routine doctor&#39;s appointments so that your blood pressure can be checked</p><p>&bull; Swelling of the face, lips, tongue, throat or other parts of the body</p><p>&bull; Seizures or fits</p><p>&bull; Symptoms of sudden fever with sweating, rapid heartbeat and muscle stiffness, which may lead to loss of consciousness.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you notice anything else that is making you feel unwell.</p><p>Other side effects not listed above may also occur in some people.</p><p>Some of these side effects (for example, increase in blood pressure, increase in blood cholesterol, changes to liver function, protein in the urine) can only be found when your doctor does tests from time to time to check your progress.</p><p>This is not a complete list of all possible side effects. Others may occur in some people and there may be some side effects not yet known</p><p>Tell your doctor if you notice anything that is making you feel unwell.</p><p>.</p><p>Tell your doctor immediately if you experience any of the following symptoms, especially if they are severe, you have not had these symptoms before or they happen very suddenly.</p><p>&bull; Anxiety or agitation</p><p>&bull; Panic attacks</p><p>&bull; Difficulty sleeping</p><p>&bull; Irritability</p><p>&bull; Aggressiveness</p><p>&bull; Hostility or impulsiveness</p><p>&bull; Restlessness</p><p>&bull; Overactivity or uninhibited behaviour</p><p>&bull; Other unusual changes in behaviour</p><p>&bull; Thoughts of suicide.</p><p>Tell your doctor immediately if you have any thoughts about suicide or doing harm to yourself.</p><p>&nbsp;</p><p><strong>Warning signs of suicide:</strong></p><p>If you or someone you know is showing the following warning signs, contact your doctor or a mental health advisor right away or go to the nearest hospital for treatment.</p><p>All thoughts or talk about suicide or violence are serious.</p><p>&bull; Thoughts or talk about death or suicide</p><p>&bull; Thoughts or talk about self-harm or doing harm to others</p><p>&bull; Any recent attempts of self-harm</p><p>&bull; An increase in aggressive behaviour, irritability or agitation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date, which is stated on the label, carton or bottle after EXP. The expiry date refers to the last day of that month.</p><p><u>Storage conditions</u></p><p>Do not store above 30&deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. </strong><strong>What Davlex contains</strong></p><p>Davlex 50mg extendeded-release film-coated tablet contain 50 mg desvenlafaxine succinate as the active ingredient.</p><p dir="RTL">Davlex 50 mg : Hypromellose 2208, Talc, microcrystalline cellulose, Magnesium Stearate, Opadry II white, Yellow Iron oxide , Red Iron Oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Davlex 50mg extendeded-release F.C.T contain :  Light pink round convex .
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p><strong>Manufacturer by:</strong></p><p>&nbsp;United Pharmaceutical Mfg. Co. Ltd.-Jordan for MS Pharma-Saudi.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Mar-2020
 SPM190358

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يستخدم هذا الدواء في الوقاية&nbsp; والعلاج&nbsp; من تكرار نوبات الاكتئاب.</p><p dir="RTL">يمكن أن يؤثر الاكتئاب على كافة الجسم، ويتسبب في إظهار أعراض نفسية وجسدية مثل الشعور بتعب وضعف النفس وعدم القدرة على الاستمتاع بالحياة ونقص أو فرط الشهية&nbsp; وتقلبات في النوم وفقدان الرغبة الجنسية</p><p dir="RTL">ونقص الحركة والشعور الدائم بالذنب على لا شيء.</p><p dir="RTL">استشر الطبيب إذا كان لديك أي سؤال فيما يتعلق بسبب وصف هذا الدواء لك، ربما قد يكون وصفه لك لسبب آخر.</p><p dir="RTL"><strong>طريقة عمل الدواء</strong></p><p dir="RTL">يحتوي دافليكس على مادة فعالة&nbsp; تسمّي ديسفينلافاكسين ساكسينات. ينتمي الدواء إلى فئة دوائية</p><p dir="RTL">&nbsp;تُدعى مثبطات السيروتونين والنورأدرينالين (SNRIs).</p><p dir="RTL">يُعتبر كل من السيروتونين والنورأدرينالين نواقل كيميائية تعمل على تنشيط أعصاب محددة في الدماغ.</p><p dir="RTL">يعمل هذا الدواء على زيادة مستوى هذه النواقل الكيميائية. حيث يعتقد الخبراء أن ذلك يساعدك في استعادة شعورك بالعافية.</p><p dir="RTL">الدواء لا يسبب الإدمان. لا يمكنك الحصول على هذا الدواء إلا بوصفة طبية من الطبيب.</p><p dir="RTL"><strong>استخدام الدواء مع الأطفال</strong></p><p dir="RTL">لم يتم التأكد حتى الآن من مدى فاعلية وأمان استخدام دواء دافليكس مع الأطفال والمراهقين الأصغر من 18 عاما</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول دافليكس في الحالات التالية:</strong></p><p dir="RTL">إذا كنت تتناول دواء آخر لعلاج الاكتئاب من فئة الأدوية المُثبطة للأكسيداز أحادي الأمَين، حتى وإن توقفت عن تناول تلك الأدوية طالما أن المدة لم تتجاوز 14 يوما.</p><p dir="RTL">إذا كانت لديك حساسية لمادة ديسفينلافاكسين أو فنلافاكسين أو لأي من المكونات الأخرى المذكورة في نهاية هذة النشرة الدوائية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يظهر رد الفعل التحسسي في صورة الأعراض الآتية:</strong></p><p dir="RTL">الطفح الجلدي</p><p dir="RTL">&bull; الشعور بالحكة وظهور الشرى على الجلد (أرتيكاريا)</p><p dir="RTL">&bull; تورم الوجه والشفاه واللسان والحلق أو أي مكان آخر من الجسم</p><p dir="RTL">&bull; قصر في النفس وأزيز الصدر ومشاكل في التنفس&nbsp; وصعوبة في البلع.</p><p dir="RTL">&nbsp; لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضحة على&nbsp; العبوة بعد كلمة EXP، أو بعد تمزق العبوة وظهور علامات تدل على تغير حالتها.</p><p dir="RTL">&nbsp; يرجى إرجاع الدواء إلى الصيدلي لكي يتخلص منه إذا مرّ تاريخ انتهاء صلاحية الدواء أو كان به تلف.</p><p dir="RTL">&nbsp; يرجى استشارة الطبيب إذا لم تكن متأكدا من مناسبة هذا الدواء لك.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>قبل تناول دافليكس:</strong></p><p dir="RTL">يجب اخبار الطبيب أو الصيدلي إن كنت تعاني من الحساسية لأي دواء آخر، أو من الطعام أو من المواد الحافظة أو من الصبغات.</p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو في حالات التخطيط لحدوث الحمل.</p><p dir="RTL">لا يُنصح بتناول دواء دافليكس أثناء الحمل. سيقوم الطبيب بمناقشة المخاطر والفوائد المحتملة من تناول هذا الدواء أثناء فترة الحمل.</p><p dir="RTL">إحدى المخاطر المحتملة من تناول الدواء وقت الحمل؛ إصابة الجنين بمشاكل عديدة بما في ذلك صعوبة في التنفس وسرعة التنفس ونوبات صرعية ونقص الأكسجين في دم الجنين وقيء وإسهال، بالإضافة لاحتمالية ظهور مشاكل جسدية وسلوكية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت دواء دافليكس أو دواء مشابه مضاد للاكتئاب في منتصف أو آخر فترة الحمل، قد تعاني من حالة تُسمى مقدمات الارتعاج (تسمم الحمل)، وتتميز بارتفاع مستمر في ضغط الدم أثناء أو بعد الحمل. قد تشمل أعراض مقدمات الارتعاج (تسمم الحمل) الصداع وألم البطن وقصر النفس</p><p dir="RTL">أو شعور بحرقان خلف عظم القص والشعور بالغثيان والقيء وتشوش الذهن وزيادة حالة القلق و / أو اختلال في الرؤية مثل فرط الحساسية للضوء وتشوش الرؤية أو رؤية بقع ومضية أو هالات ضوئية.</p><p dir="RTL">إذا تناولت دواء دافليكس أو دواء مشابه مضاد للاكتئاب في آخر شهر في فترة الحمل، قد تعاني من نزيف غزير أثناء و / أو بعد الولادة.</p><p dir="RTL">يجب عدم الاستمرار في تناول دواء دافليكس أو أي دواء مشابه مضاد للاكتئاب أثناء فترة الحمل إلا تحت التوجيه الدقيق من الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;قد تظهر أعراض انتكاس المرض إذا تم إيقاف الدواء، حتى إذا كان الاكتئاب متحكمًا به بالدواء من قبل.</p><p>&nbsp;</p><p dir="RTL"><strong>يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات التي تقوم بالرضاعة الطبيعية أو عند التخطيط للرضاعة الطبيعية.</strong></p><p dir="RTL">يُفرز الدواء في لبن الأم، لذلك من المحتمل أن يتأثر به الرضيع.</p><p dir="RTL">ولأجل ذلك، لا يُنصح بتناول هذا الدواء في حالة السيدات التي تقوم بالرضاعة الطبيعية.</p><p>&nbsp;</p><p dir="RTL"><strong>يجب إخبار الطبيب إذا كنت تعاني أو سبق وعانيت من أي مشكلة طبية، خاصة المشكلات التالية:</strong></p><p dir="RTL">&bull; تاريخ مرضي للإصابة بالصرع (التشنجات)</p><p dir="RTL">&bull; تاريخ مرضي شخصي أو عائلي للإصابة باضطراب ثنائي القطب</p><p dir="RTL">&bull; مشاكل في ضغط الدم</p><p dir="RTL">&bull; المياه الزرقاء (ارتفاع الضغط&nbsp; داخل العين)</p><p dir="RTL">&bull; العُرضة للنزيف بصورة أكبر من الطبيعي، أو إذا كنت تتناول أدوية مانعة للتجلط</p><p dir="RTL">&bull; ارتفاع في نسبة مستويات الكوليسترول أو الدهون</p><p dir="RTL">&bull; مشاكل في الكلية أو الكبد</p><p dir="RTL">&bull; مشاكل في القلب</p><p dir="RTL">&bull; نقص مستوى الصوديوم في الدم</p><p dir="RTL">&bull; أي مشكلة طبية أخرى.</p><p dir="RTL"><strong>يجب إبلاغ الطبيب إذا كنت تخطط لإجراء عملية جراحية .</strong></p><p dir="RTL">إذا لم تخبر الطبيب عن أي من هذه الأمراض والمشاكل السابق ذكرها، فمن الضروري أن تخبره عن تلك الأمراض قبل البدء في تناول الدواء.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>تناول أدوية أخرى مع دواء دافليكس</strong></p><p dir="RTL">يجب إخبار الطبيب أو الصيدليّ إذا كنت تتناول أية أدوية أخرى، بما في ذلك:</p><p dir="RTL">كافة الأدوية التي تستلزم وصفة طبية.</p><p dir="RTL">&bull; كافة الأدوية والفيتامينات والأعشاب الطبية والعلاجات الطبيعية التي تأتي بدون وصفة طبية ويمكنك شرائها من الصيدلية أو من المتاجر (السوبر ماركت) أو المعالجين الطبيعيين أو من متاجر الأغذية الصحية، على سبيل المثال: نبتة جونز أو مكملات التريبتوفان.</p><p dir="RTL">لا تتناول أي دواء آخر أثناء تناولك دواء دافليكس، إلا إذا وصفه لك الطبيب أو أقرّه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُحتمل تداخل بعض الأدوية في عمل هذا الدواء، كما يمكن أن يتدخل هذا الدواء في عمل الأدوية الأخرى. ويشمل ذلك ما يلي:</strong></p><p dir="RTL">الأدوية المضادة للاكتئاب المُسماه بالأدوية المُثبطة للأكسيداز أحادي الأمَين (مثل دواء موكلوبيمايد، فينيلزاين وترانيكلوبروماين). يجب إخبار الطبيب إذا كنت تتناول هذه الأدوية، حتى وإن توقفت عن تناول تلك الأدوية طالما أن المدة لم تتجاوز 14 يوما. استشر الطبيب&nbsp; أو الصيدلي إذا كنت لست متأكدًا من تناول أي من هذه الأدوية. يجب عدم تناول دواء دافليكس أو أي دواء آخر مشابه له أثناء أو قبل مرور ١٤ يوم على تناول أحد الأدوية المُثبطة للأكسيداز أحادي الأمَين لأن ذلك قد يتسبب في الإصابة بحالة خطيرة تهدد الحياة. استشر الطبيب&nbsp; أو الصيدلي إذا كنت تتناول أي من هذه الأدوية ليخبرك بكيفية التصرف السليم.</p><p dir="RTL">أي دواء آخر يستخدم لعلاج اضطراب ثنائي القطب، الاكتئاب، نوبات القلق والاضطراب، اضطراب الوسواس القهري أو الاضطراب الانزعاجي لما قبل الحيض ، بما في ذلك نبتة جونز.</p><p dir="RTL">الأدوية التي تؤثر في مستويات السيروتونين مثل: ترامادول، ديكستروميثورفان، فينتانيل، ميثادون، بينتازوسين.</p><p dir="RTL">الأدوية التي تستخدم في علاج اضطراب نقص الانتباه مع فرط النشاط، مثل دواء ديكسامفيتامين وليسديكسامفيتامين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية المساعدة على فقدان الوزن بما في ذلك دواء سبيوترامين.</strong></p><p dir="RTL">تريبتانس (يستخدم في علاج الصداع النصفي)</p><p dir="RTL">لينيزوليد&nbsp; (يستخدم في علاج العدوى)</p><p dir="RTL">&nbsp;&bull; الأدوية التي تجعلك أكثر عرضة للنزيف، مثل: الأسبرين، الأدوية الغير استيرودية المضادة للالتهابات، الوارفرين.</p><p dir="RTL">وفي هذه الحالة، ستحتاج إلى تناول جرعات مختلفة من هذا الدواء أو أن تتناول أدوية غيرها.</p><p dir="RTL">سيقوم الطبيب حينها بنصحك بالحل الأمثل.</p><p dir="RTL">لدى الطبيب أو الصيدلي معلومات أكثر فيما يتعلق بالأدوية الواجب توخي الحذر معها أو منعها أثناء تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>استبدال إحدى الأدوية المضادة للاكتئاب بدواء دافليكس</strong></p><p dir="RTL">إذا قمت باستبدال أحد الأدوية المضادة للاكتئاب بهذا الدواء، فإنك ستعرّض للإصابة بأعراض جانبية ناتجة عن انقطاعك عن الأدوية المضادة للاكتئاب، بما في ذلك دواء فنلافاكسين ودافليكس.</p><p dir="RTL">قد يقوم الطبيب بتقليل جرعتك الأولية من الأدوية المضادة للاكتئاب من أجل المساعدة في تقليل نسبة حدوث الأعراض الجانبية.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم ببلع القرص بأكمله باستخدام كوب من الماء أو أي سوائل غير كحولية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تقم بقسم أو تحطيم أو مضغ القرص، ولا تضعه في الماء أيضا.</p><p dir="RTL">لا تقلق إذا رأيت غلاف القرص في البراز بعد تناولك الدواء.</p><p dir="RTL">وذلك لأن القرص يسري داخل مسار الجهاز الهضمي بينما تُفرز منه مادة ديسفينلافاكسين الفعالة.</p><p dir="RTL">&nbsp;يبقى غلاف القرص دون أن يتحلل، ليتم إخراجه عبر البراز.</p><p dir="RTL">وبناءً على ذلك، فقد ترى غلاف القرص في البراز ومع ذلك قد امتص جسدك الجرعة الكاملة من المادة الفعالة ديسفينلافاكسين.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة التي يجب تناولها من الدواء</strong></p><p dir="RTL">الجرعة التقليدية من الدواء هي 50 ملغم، تؤخذ مرة في اليوم مع أو بدون الطعام.</p><p dir="RTL"><strong>لا تغير جرعة الدواء إلا إذا أخبرك الطبيب بذلك.</strong></p><p dir="RTL">سيقوم الطبيب بزيادة جرعة الدواء تدريجيا إذا رأي حاجتك لذلك.</p><p dir="RTL">إذا كنت تعاني من مشكلة في الكلى، فقد يحتاج الطبيب إلى تقليل جرعة الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>متى تتناول هذا الدواء</strong></p><p dir="RTL"><strong>تناول الجرعة المحددة لك في نفس الموعد كل يوم.</strong></p><p dir="RTL">يمكنك تتناول جرعتك المحددة في الصباح أو المساء.</p><p dir="RTL">تناول الجرعة في نفس الوقت من كل يوم سيمنحك أفضل فاعلية للدواء. كما سيساعدك ذلك أيضا على تذكر موعد تناول جرعتك من الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>مدة تناول الدواء</strong></p><p dir="RTL"><strong>استمر في تناول الدواء ما دام الطبيب يخبرك بذلك.</strong></p><p dir="RTL">بالرغم من أنك ستشعر بالتحسن بعد مرور أسبوعين إلا أنه من الممكن أن يستغرق الأمر عدة أسابيع لكي تشعر بتحسن أكثر. من المهم أن تمنح الدواء وقته الكافي للعمل.</p><p dir="RTL">يساعد هذا الدواء على التحكم في حالتك، لذلك من الضروري أن تستمر في تناول الدواء حتى لو كنت تشعر بالتحسن.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول الدواء</strong></p><p dir="RTL">تجاهل الجرعة التي نسيتها إذا كان الوقت المتبقي على موعد الجرعة القادمة أقل من 12 ساعة، ثم تناول جرعتك القادمة في وقتها المحدد. وعدا ذلك، فيمكنك تناول جرعتك من الدواء في أقرب وقت تتذكر فيه، على أن تكمل بعد ذلك على&nbsp; موعدك الذي كنت عليه.</p><p dir="RTL">لا تتناول جرعة مزدوجة لتعويض جرعتك الفائتة.</p><p dir="RTL">قد يزيد ذلك من فرص إصابتك بالأعراض الجانبية الغير مرغوبة.</p><p dir="RTL">يرجى التوجه بالسؤال للطبيب أو الصيدلي في حالة عدم تأكدك من أي شيء.</p><p dir="RTL">إذا كنت تعاني من صعوبات في تذكر موعد تناولك للدواء، فقم باستشارة الصيدلي كي يدلك على بعض النصائح والارشادات التي تساعدك.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة كبيرة جدا</strong></p><p dir="RTL"><strong>.</strong></p><p dir="RTL">إذا تناولت أنت أو أحد غيرك جرعة زائدة من الدواء، فيجب عليك التواصل فورا مع الطبيب أو مركز معلومات الأدوية والسموم&nbsp; (رقم الهاتف: 997) من أجل تلقي النصح، أو قم بالتوجه إلى قسم الطوارئ والحوادث لدى أقرب مشفى منك.</p><p dir="RTL">قم بفعل ذلك حتى لو لم تكن هنالك أية أعراض على الشعور بعدم الراحة أو التسمم.</p><p dir="RTL">من الممكن أن تكون في حاجة إلى الرعاية الطبية العاجلة.</p><p dir="RTL">اجعل هذه الأرقام في أماكن سهل الوصول إليها أثناء تناول أي دواء.</p><p>&nbsp;</p><p dir="RTL"><strong>أثناء تناولك دافليكس</strong></p><p dir="RTL"><strong>أمور يجب عليك فعلها</strong></p><p dir="RTL"><strong>تابع مع الطبيب الخاص بك باستمرار لكي يتحقق من تحسن وتطور حالتك الصحية. </strong></p><p dir="RTL"><strong>ناقش مع الطبيب كافة الأسئلة التي لديك فيما يتعلق بتناول هذا الدواء.</strong></p><p dir="RTL"><strong>تناول دواء دافليكس كما وصف لك الطبيب.</strong></p><p dir="RTL"><strong>من المهم أن تبلغ أي طبيب آخر أو طبيب الأسنان أو الصيدلي الذي يعالجك بأنك تتناول دواء دافليكس.</strong></p><p dir="RTL"><strong>احتفظ بعدد كاف من أقراص الدواء لكي يكفيك في أيام العطلات وآخر الأسبوع.</strong></p><p dir="RTL">يساعد هذا الدواء في التحكم في حالتك، لكنه لا يشفيها. لذلك من الضروري أن تستمر في تناول الدواء حتى لو كنت تشعر بالتحسن.</p><p dir="RTL"><strong>تابع بحذر ظهور أية أعراض تشير إلى أن الاكتئاب يزداد سوءا، خاصة في أول أسبوعين من العلاج وأيضا عند تغيير الجرعة.</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">قد يشعر بعض المرضى في بعض الأحيان بأن أعراض الاكتئاب لديهم تزداد سوءا. يمكن أن يحدث ذلك حتى وإن كنت تتناول الأدوية المضادة للاكتئاب.</p><p dir="RTL">أخبر طبيبك أن هنالك احتمالية أن تكون نتيجة اختبار المخدرات في البول إيجابية كاذبة إذا كنت تتناول دواء دافليكس.</p><p dir="RTL"><strong>أخبر طبيبك فور ملاحظة أي من هذه الأعراض؛ خاصة إن كانت الأعراض شديدة، أو لم تصب بها من قبل، أو حدثت بشكل مفاجئ.</strong></p><p dir="RTL">الاضطراب والانفعال</p><p dir="RTL">نوبات الفزع</p><p dir="RTL">صعوبة في النوم</p><p dir="RTL">التهيّج العصبي</p><p dir="RTL">العدوانية</p><p dir="RTL">&bull; العداء أو الاندفاع</p><p dir="RTL">القلق</p><p dir="RTL">&bull; فرط النشاط أو سلوك غير حساس (خارج عن الإدراك)</p><p dir="RTL">&bull; تغيرات أخرى غير معتادة في السلوك</p><p dir="RTL">&bull; أفكار انتحارية.</p><p dir="RTL"><strong>يجب إبلاغ الطبيب على الفور إذا كانت تراودك أي أفكار تتعلق بالانتحار أو أذية النفس.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>العلامات التحذيرية للانتحار:</strong></p><p dir="RTL"><strong>يجب عليك التواصل مع الطبيب أو اختصاصي الصحة العقلية أو التوجه إلى المستشفى على الفور من أجل تلقي العلاج إذا ظهرت لك أو لغيرك أي من هذه العلامات التحذيرية.</strong></p><p dir="RTL">يجب أخذ كافة الأفكار والكلام حول الانتحار أو العنف على محمل الجد.</p><p dir="RTL">&bull; أفكار أو كلام عن الموت أو الانتحار</p><p dir="RTL">&bull; أفكار أو كلام عن أذية النفس أو الغير</p><p dir="RTL">&bull; أية محاولات لأذية النفس في الوقت الحالي</p><p dir="RTL">&bull; زيادة في السلوك العدواني أو التهيج أو الانفعال العصبي</p><p>&nbsp;</p><p dir="RTL"><strong>أمور يجب عليك الحذر منها</strong></p><p dir="RTL"><strong>توخ الحذر عند القيادة أو استخدام الآلات الخطيرة حتى تعرف كيف يؤثر هذا الدواء عليك.</strong></p><p dir="RTL">يتسبب تناول هذا الدواء بالشعور بالنعاس.</p><p>&nbsp;</p><p dir="RTL"><strong>أمور يجب عليك عدم&nbsp; فعلها</strong></p><p dir="RTL"><strong>لا تتوقف عن تناول الدواء&nbsp; حتى إذا شعرت بالتحسن ولا تغير جرعته أيضا، إلا إذا أخبرك الطبيب بذلك.</strong></p><p dir="RTL">من الممكن أن يقوم الطبيب بتقليل جرعة الدواء ببطء من أجل المساعدة في تجنب حدوث الأعراض الجانبية. الأعراض الجانبية</p><p dir="RTL">تحدث الأعراض الجانبية عندما يتوقف المرضى عن تناول الدواء، خاصة عند حالات التوقف المفاجئ.</p><p dir="RTL">تشمل بعض هذه الأعراض الجانبية على الآتي:</p><p dir="RTL">صداع</p><p dir="RTL">غثيان</p><p dir="RTL">دوار</p><p dir="RTL">هبوط</p><p dir="RTL">التهيّج العصبي</p><p dir="RTL">قلق أو اضطراب</p><p dir="RTL">أحلام غير طبيعية</p><p dir="RTL">إسهال</p><p dir="RTL">العرق بغزارة</p><p dir="RTL">&bull; اختلال في الرؤية</p><p dir="RTL">&bull; ارتفاع ضغط الدم</p><p dir="RTL">التقليل المتدرج البطيء من جرعة الدواء يساعد في تقليل نسبة حدوث&nbsp; هذه الأعراض الجانبية. قد يتطلب حدوث ذلك على مدى أشهر طويلة أو أكثر من ذلك.</p><p dir="RTL">يمكن أن يتسبب بعض هذه الأعراض في مشاكل عند القيادة أو استخدام الأجهزة والآلات الخطيرة.</p><p dir="RTL">يجب عليك تجنب هذه الأنشطة إذا لاحظت أي من هذه الأعراض.</p><p dir="RTL">لا تتناول المشروبات الكحولية أثناء تناولك هذا الدواء.</p><p dir="RTL">يجب عدم إعطاء هذا الدواء إلى أي شخص آخر حتى لو كانت أعراض مرضه مشابهةً لأعراض مرضك.</p><p>&nbsp;</p><p dir="RTL">الخفقان أو قصر النفس أو الألم الشديد في الصدر أو عدم انتظام ضربات القلب.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أخبر الطبيب أو الصيدلي في أقرب وقت ممكن عند ملاحظة الشعور بعدم الارتياح أثناء تناولك دافليكس.</p><p dir="RTL">كافة الأدوية لها أعراض جانبية. في البعض الأحيان قد تكون تلك الأعراض خطيرة جدا، ولكن في أغلب الأحيان قد لا تكون كذلك. من الممكن أن تكون في حاجة إلى الرعاية الطبية إذا عانيت من بعض هذه الأعراض الجانبية.</p><p dir="RTL">يصعب تحديد أي من هذه الأعراض الجانبية ناتج عن تناولك هذا الدواء أوعن تناول دواء غيره أو أن الأعراض الجانبية هي أعراض مرضك الأساسي. وبناء على هذا السبب، فمن الضروري أن تخبر الطبيب إذا حدث أي تغير في حالتك الصحية.</p><p dir="RTL">لا تشعر بالقلق من كل هذه الأعراض الجانبية.</p><p dir="RTL">فمن المحتمل أنك لن تصاب بأي من هذه الأعراض.</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إبلا غ الطبيب إذا...</p><p dir="RTL">أخبر الطبيب فور ملاحظة أي من هذه الأعراض الآتية إن كانت تُقلقك:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في المعدة والأمعاء أو القناة البولية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التبول</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات سلوكية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم، نوم غير طبيعي، أحلام غير طبيعية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في العلاقة الجنسية مثل؛ فقدان الرغبة الجنسية، تأخر القذف، مشاكل في الانتصاب أو صعوبات في الوصول للنشوة الجنسية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيّج العصبي أو الاضطراب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتوتر والانفعال</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التفكير أو العمل بسبب:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التثاؤب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال التركيز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء أو الدوار بعد الوقوف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهبوط</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العرق بغزارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سخونة واحمرار الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين الأذن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق، جفاف الفم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p dir="RTL">أخبر طبيبك في أقرب وقت ممكن عند ملاحظة أي من هذه الأعراض:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العضلات، تيبس، ضعف أو اختلال في الحركة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير طبيعية في الوجه مثل دسر اللسان (دفع اللسان للأسنان الأمامية)، المضغ المتكرر، تأرجح الفكين أو التكشير</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور باللامبالاة أو فقدان الاهتمام بما حولك</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بأن نفسك منفصلة عنك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهلوسة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الذهن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيج العصبي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط على غير العادة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس، قصر النفس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف أو سهولة تكون الكدمات أكثر من الطبيعي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنميل (خدر) أو شعور بوخز الإبر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية من ضوء الشمس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توجه إلى المستشفى عند حدوث...</strong></p><p dir="RTL">يجب عليك إبلاغ الطبيب على الفور أو التوجه إلى قسم الطوارئ والحوادث لدى أقرب مشفى منك إذا لاحظت أي من الأعراض الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم حاد في الجزء العلوي من البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم وإيلام عند لمس البطن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع أو انخفاض في ضغط الدم من الممكن أن تصاب بالصداع، تشوش الرؤية، خفقان القلب، تشوش الذهن أو فقدان الوعي. وفي بعض الأحيان قد لا تصاب بأي من هذه الأعراض. يجب عليك الانتظام في مواعيد زيارة الطبيب الروتينية من أجل متابعة مستوى ضغط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه والشفاه واللسان والحلق أو أي مكان آخر من الجسم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات صرعية أو تشنجات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مفاجئة بارتفاع درجة الحرارة مع العرق وسرعة ضربات القلب وتيبس العضلات، والتي قد تؤدي إلى فقدان الوعي.</p><p dir="RTL">يجب إخبار الطبيب أو الصيدلي إذا لاحظت وجود أي شيء آخر يزعجك.</p><p dir="RTL">يمكن أن تحدث بعض الأعراض الجانبية غير المذكورة بالأعلى في بعض الأشخاص.</p><p dir="RTL">ومثال على مثل هذه الأعراض الجانبية (ارتفاع ضغط الدم، ارتفاع مستوى الكولسترول، تغيرات في وظائف الكبد، نزول البروتين في البول). لن تعرف بوجود هذه الأعراض الجانبية إلا إذا قام الطبيب بإجراء فحوصات من وقت لآخر من أجل متابعة حالتك.</p><p dir="RTL">لا تحتوي هذه القائمة على كافة الأعراض الجانبية المتوقعة من تناول هذا الدواء. يمكن أن تحد أعراض جانبية غير المذكورة في بعض المرضى، كما أنه من المحتمل أن تكون هنالك أعراضا جانبية غير معروفة حتى الآن.</p><p dir="RTL">يجب إخبار الطبيب أو الصيدلي إذا لاحظت وجود أي شيء آخر يزعجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك فور ملاحظة أي من هذه الأعراض؛ خاصة إن كانت الأعراض شديدة، أو لم تُصب بها من قبل، أو حدثت بشكل مفاجئ:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطراب والانفعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات الفزع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهيّج</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوانية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العداء أو الاندفاع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط أو سلوك غير حساس (خارج عن الإدراك)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات أخرى في السلوك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار انتحارية.</p><p dir="RTL">يجب عليك إبلا غ الطبيب على الفور إذا كانت لديك أية أفكار تتعلق بالانتحار أو أذية النفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>العلامات التحذيرية للانتحار</strong><strong>:</strong></p><p dir="RTL">يجب عليك التواصل مع الطبيب أو اختصاصي الصحة العقلية أو التوجه إلى المشفى على الفور من أجل تلقي العلاج إذا ظهرت لك أو لغيرك أي من هذه العلامات التحذيرية.</p><p dir="RTL">يجب أخذ كافة الأفكار والكلام حول الانتحار أو العنف على محمل الجد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار أو كلام عن الموت أو الانتحار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفكار أو كلام عن أذية النفس أو الغير</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أية محاولات لأذية النفس في الوقت الحالي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في السلوك العدواني أو التهيج أو الانفعال العصبي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضحة على شريط الأقراص وعلى العبوة بعد كلمة EXP.</p><p dir="RTL">يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">لا تحفظ الدواء &nbsp;في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">لا تقم بإلقاء أي أدوية في مياه الصرف أو في النفايات المنزلية، وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محتويات <strong>دافليكس</strong>:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>المادة الفعالة</u>: ديسفينلافاكسين ساكسينات.</p><p dir="RTL">يحتوي كل قرص مغلف ممتد المفعول من <strong>دافليكس 50 ملغم </strong>على: 50 ملغم من المادة الفعالة ديسفينلافاكسين ساكسينات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>باقي المكونات</u>:</p><p dir="RTL">هيبروميلوس2208 ، التالك ، سليلوز دقيق البلورات ،&nbsp; واستيارات الماغنيسيوم، أوبادري 2 الأبيض ، أكسيد الحديد الأصفر ، وأكسيد الحديد الأحمر .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دافليكس </strong><strong>5</strong><strong>0 ملغم</strong><strong> أقراص ممتدة المفعول :</strong> ذات لون زهري فاتح مستديرة محدبة .</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">info-ksa@mspharma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:</strong></p><p dir="RTL">المتحدة للصناعات الدوائية- الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Mar-2020
SPM190358

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Davelx 50 mg Extended Release Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Davelx is formulated as an Extended -release tablet for once-a-day oral administration..
Each tablet contain 50 mg Desvenlafaxine (as Succinate monohydrate)
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Extended Release Film-coated tablet (tablet).
Davelx  50 mg:
Light pink round convex .


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Davelx is indicated for the treatment of adults with major depressive disorder (MDD)</p><p>Depression can affect your whole body and may cause emotional and physical symptoms such as feeling low in spirit, being unable to enjoy life, poor appetite or overeating, disturbed sleep, loss of sex drive, lack of energy and feeling guilty over</p><p>nothing.</p><p>Davelx is not indicated for paediatric use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dose</strong></p><p>Davelx should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.</p><p><strong>Initial Treatment </strong></p><p>The recommended dose for Davelx is 50 mg once daily, with or without food. In clinical trials, no additional benefit was demonstrated at doses greater than 50 mg/day. Based on clinical judgment, if dose increases are indicated for individual patients, they should occur gradually and at intervals of not less than 7 days. The maximum dose should not exceed 200 mg/day.</p><p>When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimise discontinuation symptoms (see PRECAUTIONS and ADVERSE EFFECTS<strong>)</strong>.</p><p>&nbsp;</p><p><strong>Maintenance/Continuation/Extended Treatment </strong></p><p>It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacological therapy. Patients should continue on the same dose at which they were stabilized. They should be periodically reassessed to determine the need for continued treatment.</p><p><strong>Children and Adolescents </strong></p><p>Safety and efficacy in patients less than 18 years of age have not been established.</p><p><strong>Dosage Adjustment in Renal Impairment </strong></p><p>The recommended starting dose in patients with severe renal impairment (24-hr CrCl &lt;30 mL/min) or end-stage renal disease (ESRD) is 50 mg every other day. Because of individual variability in clearance in these patients, individualisation of dosage may be desirable. Supplemental doses should not be given to patients after dialysis (see PHARMACOLOGY).</p><p><strong>Dosage Adjustment in Hepatic Impairment </strong></p><p>No adjustment of dose is necessary in patients with mild, moderate, and severe hepatic impairment (see PHARMACOLOGY).</p><p><strong>Dosage Adjustment in the Elderly </strong></p><p>No dosage adjustment is required solely on the basis of age; however, possible reduced renal clearance of Davelx should be considered when determining dose (see PHARMACOLOGY).</p><p><strong>Discontinuing Davelx </strong></p><p>When discontinuing therapy gradual dose reduction should be considered to minimise discontinuation symptoms (see PRECAUTIONS and ADVERSE EFFECTS).</p><p>&nbsp;</p><p>Symptoms associated with discontinuation of Davelx, as well as other SNRIs and SSRIs have been reported (see PRECAUTIONS). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate (see PRECAUTIONS and ADVERSE EFFECTS). In some patients, discontinuation may need to occur over periods of months or longer.</p><p><strong>Switching Patients from Other Antidepressants to Davelx </strong></p><p>Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine to desvenlafaxine. Tapering of the initial antidepressant followed by a washout period may be necessary to minimise discontinuation symptoms and the possibility of drug-drug interactions from a pharmacokinetic or pharmacodynamic perspective.</p><p><strong>Residual Inert Tablet Matrix </strong></p><p>Patients receiving Davelx may notice an inert matrix tablet passing in the stool or via colostomy.</p><p>Patients should be informed that the active medication has already been absorbed by the time the patient sees the inert matrix tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4.3 Contraindications
Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or to any excipients in the Davelx formulation. 
Monoamine Oxidase Inhibitors (MAOIs) 
Davelx must not be used in combination with monoamine oxidase inhibitors (MAOIs) or reversible MAOIs (RIMA) (e.g. moclobemide, linezolid and intravenous methylene blue), or within 14 days of discontinuing treatment with a MAOI. Similarly, Davelx must be discontinued for at least 7 days before starting treatment with a MAOI. Cases of serious reactions, such as potentially life-threatening serotonin syndrome (characterised by neuromuscular excitation, altered mental status  and autonomic dysfunction) have been reported in patients receiving an SNRI in combination with MAOIs and RIMA, and in patients who have recently discontinued an SNRI and have been started on a MAOI (see also PRECAUTIONS and INTERACTIONS WITH OTHER MEDICINES).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical Worsening and Suicide Risk </strong></p><p>Patients with major depression, both adult and paediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behaviour (suicidality) or unusual changes in behaviour, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. Antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. As improvement may not occur during the first few weeks or more of treatment, patients should be monitored appropriately and observed closely for clinical worsening and suicidality, especially at the beginning of a course of treatment or at the time of dose changes, either increases or decreases.</p><p>Pooled analyses of short-term placebo-controlled trials of antidepressant medicines (SSRIs and others) showed that these medicines increase the risk of suicidality in children, adolescents, and young adults (ages 18-24 years) with major depression and other psychiatric disorders, generally during initial treatment (1-2 months). Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond the age of 24 years; there was a reduction in the risk of suicidality with antidepressants compared to placebo in adults age 65 years and older.</p><p>The pooled analysis of placebo-controlled trials in children and adolescents with major depression, obsessive compulsive disorder, or other psychiatric disorders included a total of 24 short-term trials of nine antidepressant medicines in over 4400 patients. The pooled analyses of placebo-controlled trials in adults with major depression or other psychiatric disorders included a total of 295 short-term trials (medium duration 2 months) of 11 antidepressant medicines in over 77,000 patients. There was considerable variation in risk of suicidality among medicines, but a tendency toward an increase in the younger patients for almost all medicines studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence with major depression.</p><p>No suicides occurred in any of the paediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about the medicine effect on suicide.</p><p>It is unknown whether the suicidality risk extends to longer-term use, i.e. beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression.</p><p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or whose emergent suicidality is severe, abrupt in onset, or was not part of the patient&rsquo;s presenting symptoms (see <strong>Discontinuation Effects </strong>below).</p><p>It is particularly important that monitoring be undertaken during the initial course of antidepressant treatment or at times of dose increase or decrease.</p><p>Patients with co-morbid depression associated with other psychiatric or non-psychiatric disorders being treated with antidepressants should be similarly observed for clinical worsening and suicidality.</p><p>Symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania and mania, have been reported in adults, adolescents and children being treated with antidepressants for major depression as well as for other indications, both psychiatric and non-psychiatric. Although a causal link between the emergence of such symptoms and either worsening of depression and /or emergence of suicidal impulses has not been established, there is concern that such symptoms may be precursors of emerging suicidality.</p><p>Prescriptions for Davelx should be written for the smallest quantity of tablets consistent with good patient management in order to reduce the possibility of overdosage. This is particularly so at the times of treatment initiation or dosage change.</p><p><strong>Information for Patients and Caregivers </strong></p><p>Patients and their caregivers should be alerted about the need to monitor for the emergence of anxiety, agitation, panic attacks, insomnia, hostility, impulsivity, akathisia, hypomania, mania, worsening of depression, and suicidal ideation, especially early during antidepressant treatment. Such symptoms should be reported to the patient&rsquo;s doctor, especially if they are severe, abrupt in onset, or were not part of the patient&rsquo;s presenting symptoms.</p><p><strong>Discontinuation Effects </strong></p><p>During marketing of SNRIs (Serotonin and Noradrenaline Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paraesthesias, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored when discontinuing treatment with Davelx. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered (see ADVERSE EFFECTS and METHOD OF ADMINISTRATION). In some patients, discontinuation may need to occur over periods of months or longer.</p><p><strong>Sexual Dysfunction</strong></p><p>SNRIs may cause symptoms of sexual dysfunction (see section 4.8 Adverse effects (undesirable effects)). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SNRIs.</p><p><strong>Mania/Hypomania </strong></p><p>In clinical trials, mania was reported for approximately 0.1% of patients treated with Davelx. Activation of mania/hypomania has also been reported in a small proportion of patients with mood disorders who were treated with other marketed antidepressants. A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder . Whether any of the symptoms represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that Davelx is not approved for use in treating bipolar depression.</p><p>As with all antidepressants, Davelx should be used cautiously in patients with a history or family history of mania or hypomania.</p><p><strong>Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions </strong></p><p>The development of a potentially life-threatening serotonin or neuroleptic malignant syndrome (NMS)-like reactions syndrome may occur with Davelx treatment, particularly with concomitant use of other serotonergic drugs (including SSRIs, SNRIs and triptans) and with drugs that impair metabolism of serotonin (e.g. MAOIs, including reversible MAOIs such as moclobemide, linezolid and intravenous methylene blue), or with antipsychotics or other dopamine antagonists (see CONTRAINDICATIONS).</p><p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, confusion, hallucinations, and coma), autonomic instability (e.g., diaphoresis, tachycardia, labile blood pressure, and hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, myoclonus, tremor) and/or gastrointestinal symptoms (e.g., nausea, vomiting, and diarrhea). Serotonin syndrome, in its most severe form can resemble NMS, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs and mental status changes (see INTERACTIONS WITH OTHER MEDICINES).</p><p>If concomitant treatment with Davelx and other agents that may affect the serotonergic and/or dopaminergic neurotransmitter system (such as an SSRI, another SNRI, amphetamines or a 5-hydroxytryptamine receptor agonist (triptan)) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p><p>The concomitant use of Davelx with serotonin precursors (such as tryptophan supplements) is not recommended.</p><p>Treatment with Davelx should be discontinued if serotonin syndrome or NMS-Like reactions occur and supportive symptomatic treatment initiated.</p><p><strong>Narrow-Angle Glaucoma </strong></p><p>Patients with raised intraocular pressure (IOP) or narrow angle glaucoma were excluded from all Davelx studies. Mydriasis has been reported in association with Davelx. It is recommended that patients with raised intra-ocular pressure or patients at risk for acute narrow-angle glaucoma (angle closure glaucoma) should be closely monitored.</p><p><strong>Co-administration of Drugs Containing Venlafaxine and/or Desvenlafaxine </strong></p><p>Desvenlafaxine is the major active metabolite of venlafaxine, a medication used to treat major depressive, generalized anxiety, social anxiety and panic disorders. Products containing desvenlafaxine succinate should not be used concomitantly with products containing venlafaxine hydrochloride or other products containing desvenlafaxine succinate.</p><p><strong>Effects on Blood Pressure </strong></p><p>Increases in blood pressure were observed in some patients in clinical trials, particularly with higher doses. Pre-existing hypertension should be controlled before treatment with Davelx. Patients receiving Davelx should have regular monitoring of blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with Davelx. Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving Davelx, either dose reduction or discontinuation should be considered. Caution should be exercised in treating patients with underlying conditions that might be compromised by increases in blood pressure.</p><p><strong>Cardiovascular/Cerebrovascular Disease </strong></p><p>Caution is advised in administering Davelx to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders (see ADVERSE EFFECTS). Increases in blood pressure and heart rate were observed in clinical trials with Davelx. Davelx has not been evaluated systematically in patients with a recent history of myocardial infarction, unstable heart disease, uncontrolled hypertension, or cerebrovascular disease. Patients with these diagnoses, except for cerebrovascular disease, were excluded from clinical trials.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Serum Lipids </strong></p><p>In the short-term, placebo-controlled, pre-marketing trials for MDD, Davelx treatment was associated with mean increases of 5.7, 1.4, 3.6 and 5.5 mg/dl in total cholesterol, HDL, LDL cholesterol and triglycerides, respectively (0.11, 0.03, 0.07 and 0.04 mmol/L, respectively). The changes in fasting serum total cholesterol, LDL, and triglycerides were dose-related. Measurement of serum lipids should be considered during treatment with Davelx.</p><p><strong>Seizures </strong></p><p>Cases of seizures have been reported in clinical trials with Davelx. Davelx has not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from clinical trials. Davelx should be prescribed with caution in patients with a seizure disorder.</p><p><strong>Abnormal Bleeding </strong></p><p>Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), including desvenlafaxine, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, haematoma, epistaxis, and petechiae to life-threatening haemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of desvenlafaxine and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding.</p><p><strong>Hyponatraemia </strong></p><p>Cases of hyponatraemia and/or the Syndrome of Inappropriate Anti-Diuretic Hormone (SIADH) secretion have been described with SNRIs (including desvenlafaxine succinate) and SSRIs, usually in volume-depleted or dehydrated patients, including elderly patients and patients taking diuretics (see ADVERSE EFFECTS).</p><p><strong>Physical and Psychological Dependence </strong></p><p>Although desvenlafaxine succinate has not been systematically studied in preclinical or clinical trials for its potential for abuse, no indication of drug-seeking behaviour was seen in the clinical trials. However, it is not possible to predict on the basis of pre-marketing experience, the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of desvenlafaxine succinate (e.g., development of tolerance, incrementation of dose, drug-seeking behaviour).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Electroconvulsive Therapy </strong></p><p>There are no clinical data establishing the risks and/or benefits of electroconvulsive therapy combined with desvenlafaxine treatment for MDD.</p><p><strong>Antidepressants and post-partum haemorrhage </strong></p><p>A retrospective cohort study of 332,224 pregnancies among 225,973 women demonstrated an increased risk of post-partum haemorrhage (PPH) in mothers exposed to SNRI therapy in the last month of pregnancy. The adjusted odd-ratio (OR) for an increased risk of PPH in mothers exposed to a SNRI in the final month of pregnancy was 1.76 (95% CI 1.47-2.11) compared to non-exposed mothers. A meta-analysis of 8 case control and cohort studies showed a 32% increase in the risk of PPH in patients exposed to antidepressants. The pooled sample size of the meta analysis was 572,686 pregnancies, and there were 48,784 cases of PPH. &nbsp;</p><p>The risk of PPH was affected by type of antidepressant, mode of delivery and time of exposure. For type of antidepressant, the most pronounced risk was found among SNRI users (Relative Risk [RR]=1.62; 95% CI 1.41-1.85). A higher risk was found in exposed patients who underwent Caesarean sections (RR=2.02, 95% CI 1.61-2.54) compared to vaginal delivery (RR=1.43, 95% CI 1.15-1.78). There was no increase in risk of PPH associated with past use of antidepressants. However, there was a further increase in risk among recent SNRI users (RR=1.73, 95% CI 1.5-2.0) and current SNRI users (RR = 1.79, 95% CI 1.53-2.10).</p><p><strong>Paediatric Use </strong></p><p>Safety and effectiveness in patients less than 18 years of age have not been established.</p><p><strong>Use in the Elderly </strong></p><p>No dosage adjustment is required solely on the basis of age; however, possible reduced renal clearance of desvenlafaxine should be considered when determining dose (see METHOD OF ADMINISTRATION and PHARMACOLOGY - Pharmacokinetics).</p><p>Greater sensitivity to desvenlafaxine in some older patients cannot be ruled out.</p><p>Of the 3,292 patients in pre-marketing clinical trials of Davelx for major depressive disorder, 5% were 65 years of age or older. No overall differences in safety or efficacy were observed between these subjects and younger subjects; however, in the short-term placebo-controlled trials, there was a higher incidence of systolic orthostatic hypotension in patients &ge; 65 years of age compared to patients &lt;65 years of age treated with Davelx.</p><p><strong>Carcinogenicity, Mutagenicity and Teratogenicity </strong></p><p><strong>Carcinogenicity </strong></p><p>Desvenlafaxine succinate did not increase the incidence of tumours in long-term mouse and rat carcinogenicity studies at oral doses up to7 (mice), 14 (male rats) and 23 (female rats) times the maximal recommended human dose of 200 mg/day, on a mg/m2 basis.</p><p><strong>Genotoxicity </strong></p><p>Desvenlafaxine was not genotoxic in in vitro assays for bacterial gene mutation, mammalian gene mutation, chromosomal aberrations and cell transformation, or in in vivo tests for clastogenic activity in mice and rats.</p><p><strong>Teratogenicity </strong></p><p>Desvenlafaxine was not teratogenic in rats at an oral dose resulting in a drug exposure (plasma AUC) that was 7 times that in humans treated with 200 mg/day. There were tendencies for reduced numbers and bodyweights of fetuses with this dose in some studies. No teratogenicity was observed in a rabbit embryo-fetal development study, but the oral doses resulted in drug exposures (AUC) that were below the value in humans treated with 200 mg/day. Potential effects on embryo-fetal development may therefore not have been fully defined due to excessive maternal toxicity at higher dosages in rabbits.</p><p>Oral administration of desvenlafaxine to pregnant rats from early gestation to weaning was associated with increased post-partum pup mortality and reduced birth weight persisting to maturity, but no effect on developmental indices, at maternal exposure (plasma AUC) 7 times that in humans treated with 200 mg/day. Maternal toxicity was observed at this dose; at the no-effect dose maternal exposure was 2 times that in humans treated with 200 mg/day.</p><p><strong>Effects on Laboratory Tests </strong></p><p>False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Monoamine Oxidase Inhibitors </strong></p><p>Adverse reactions, some of which were serious, have been reported in patients who have recently been discontinued from a monoamine oxidase inhibitor (including reversible MAOIs such as moclobemide, linezolid and intravenous methylene blue) and started on antidepressants with pharmacological properties similar to desvenlafaxine (SNRIs or SSRIs), or who have recently had SNRI or SSRI therapy discontinued prior to initiation of an MAOI (see PRECAUTIONS). Concomitant use of desvenlafaxine in patients taking monoamine oxidase inhibitors is contraindicated (see CONTRAINDICATIONS).</p><p><strong>Central Nervous System (CNS)-Active Agents </strong></p><p>The risk of using desvenlafaxine succinate in combination with other CNS-active drugs has not been systematically evaluated. Consequently, caution is advised when Davelx is taken in combination with other CNS-active drugs.</p><p><strong>Serotonin Syndrome </strong></p><p>As with other serotonergic agents, serotonin syndrome, a potentially life threatening condition, may occur with desvenlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system (including triptans, SSRIs, other SNRIs, amphetamines, lithium, sibutramine, fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, pethidine, methadone, pentazocine or St. John&rsquo;s wort [Hypericum perforatum]), with drugs which impair metabolism of serotonin (such as MAOIs including moclobemide, linezolid [an antibiotic which is a reversible non-selective MAOI] and intravenous methylene blue), or with serotonin precursors (such as tryptophan supplements). Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular aberrations and/or gastrointestinal symptoms (see CONTRAINDICATIONS and PRECAUTIONS).</p><p>If concomitant treatment with Davelx and other agents that may affect the serotonergic neurotransmitter system (such as an SSRI, another SNRI or a 5-hydroxytryptamine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of desvenlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended (see PRECAUTIONS).</p><p><strong>Ethanol </strong></p><p>A clinical study has shown that Davelx does not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking Davelx.</p><p><strong>Potential for Other Drugs to Affect Desvenlafaxine </strong></p><p><strong>Inhibitors of CYP3A4 </strong></p><p>CYP3A4 is minimally involved in desvenlafaxine elimination. In a clinical study, ketoconazole (200 mg BID) increased the AUC of desvenlafaxine (400 mg single dose) by approximately 43%, a weak interaction. Concomitant use of desvenlafaxine with potent inhibitors of CYP3A4 may result in higher exposure to desvenlafaxine.</p><p><strong>Inhibitors of other CYP enzymes </strong></p><p>Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of desvenlafaxine.</p><p><strong>Potential for Desvenlafaxine to Affect Other Drugs </strong></p><p><strong>Drugs metabolised by CYP2D6 </strong></p><p>When desvenlafaxine was administered at a dose of 400 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased approximately 90%. Concomitant use of desvenlafaxine with a drug metabolised by CYP2D6 may result in higher concentrations of that drug.</p><p><strong>Drugs metabolized by CYP3A4 </strong></p><p>In vitro, desvenlafaxine does not inhibit, or induce the CYP3A4 isozyme.</p><p>In a clinical study, desvenlafaxine (400 mg daily) decreased the AUC of midazolam (a single 4 mg dose), by approximately 31%. Concomitant use of desvenlafaxine with a drug metabolised by CYP3A4 may result in lower exposures to that drug.</p><p><strong>Drugs metabolised by CYP1A2, 2A6, 2C8, 2C9 and 2C19 </strong></p><p>In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes.</p><p><strong>P-glycoprotein Transporter </strong></p><p>In vitro, desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein transporter.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy </u></p><p><strong>CATEGORY B2. </strong></p><p>The safety of Davelx in human pregnancy has not been established. Studies have demonstrated that desvenlafaxine crosses the human placenta. Only administer Davelx to pregnant women if the expected benefits outweigh any possible risk. If Davelx is used until, or shortly before birth, discontinuation effects in the newborn should be considered.</p><p>Neonates exposed to venlafaxine, other SNRIs (Serotonin and Noradrenaline Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring extendeded hospitalisation, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, irritability and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the new born (PPHN). This potential risk cannot be ruled out with desvenlafaxine taking into account the related mechanism of action (inhibition of the re-uptake of serotonin).</p><p>A small prospective, observational study consisted of 56 mother-infant pairs: 18 controls and 38 SSRI/SNRI mother-infant pairs. Of these, 11 mother-infant pairs were exposed to venlafaxine. The median (interquartile range [IQR]) gestational age was higher in infants born to control mothers than those born to mothers treated with antidepressants (40 [39-40 weeks] versus 39 [38-40 weeks]; p&lt;0.05). Neonates born to control mothers also had a longer median (IQR) length at birth (51 [49-51.6] cm versus 49 [47-51] cm; p&lt;0.05) than infants born to mothers in the cases group. The infants also displayed mild behavioural anomalies, categorised as less optimal functioning for habituation and motor and autonomic clusters (using the Brazelton Neonatal Behavioural Assessment Scale [BNBAS]); however these events were self-limiting and usually resolved in 1 to 2 weeks.</p><p>In another study, 6 of the 7 neonates with in utero exposure to venlafaxine at near term had acceptable Apgar scores at birth; however an improvement in Apgar scores at 5 minutes was observed in all 7 neonates. No cases of intrauterine growth retardation were recorded. The adverse events observed in 5 neonates at birth, included respiratory distress, tachypnoea, irritability, tremors, excessive suckling, rigidity, increased tonus, vomiting, hyper reflexia, disorganised movements of limbs, initial decreased reactivity, agitation, poor sleep and liquid/abundant stool. In 4 of the 5 neonates, the events resolved spontaneously without the need for any pharmacological treatment, while one neonate required resuscitation and continuous positive airway pressure (C-PAP) for 48 hours.</p><p>A prospective longitudinal study of 201 women with a history of major depression who were euthymic at the beginning of pregnancy showed that women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.</p><p>Exposure to SNRIs in mid to late pregnancy may increase the risk for preeclampsia, and exposure to SNRIs near delivery may increase the risk for postpartum haemorrhage.</p><p><u>Teratogenicity<strong> </strong></u></p><p>Desvenlafaxine was not teratogenic in rats at an oral dose resulting in a drug exposure (plasma AUC) that was 7 times that in humans treated with 200 mg/day. There were tendencies for reduced numbers and bodyweights of fetuses with this dose in some studies. No teratogenicity was observed in a rabbit embryo-fetal development study, but the oral doses resulted in drug exposures (AUC) that were below the value in humans treated with 200 mg/day. Potential effects on embryo-fetal development may therefore not have been fully defined due to excessive maternal toxicity at higher dosages in rabbits.</p><p>Oral administration of desvenlafaxine to pregnant rats from early gestation to weaning was associated with increased post-partum pup mortality and reduced birth weight persisting to maturity, but no effect on developmental indices, at maternal exposure (plasma AUC) 7 times that in humans treated with 200 mg/day. Maternal toxicity was observed at this dose; at the no-effect dose maternal exposure was 2 times that in humans treated with 200 mg/day.</p><p><u>Lactation </u></p><p>Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from desvenlafaxine, a decision should be made whether or not to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p><p>Davelx should only be taken by breastfeeding women if the expected benefits outweigh any possible risk.</p><p><u>Fertility</u></p><p>Fertility in male rats was unaffected by oral administration of desvenlafaxine resulting in exposure (plasma AUC) up to 4 times that in humans treated with 200 mg/day. When treated male rats were mated with treated females, female fertility was variably reduced with oral doses resulting in exposures (plasma AUC) 2 to 7 times that in humans treated with 200 mg/day; there was some evidence that this was associated with disruption of oestrus cycles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The results of a clinical study that assessed the effects of desvenlafaxine on behavioural performance of healthy individuals revealed no clinically significant impairment of psychomotor, cognitive, or complex behaviour performance. However, since any CNS-active drug may impair judgement, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Davelx therapy does not adversely affect their ability to engage in such activities.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>The safety of desvenlafaxine was established in a total of 4,724 patients, who were exposed to at least one dose of desvenlafaxine ranging from 50 to 400 mg/day in clinical trials. Long-term safety was evaluated in 1,576 patients, who were exposed to desvenlafaxine for at least 6 months and with 575 patients exposed for 1 year.</p><p>The following list of adverse reactions was reported by patients treated with desvenlafaxine throughout the dose range studied (50 to 400 mg) during both short- and long-term trials. In general, the adverse reactions were most frequent in the first week of treatment.</p><p>Adverse reactions are listed below in CIOMS frequency categories:</p><p>Very Common &ge;10%</p><p>Common: &ge;1 % and &lt;10%;</p><p>Uncommon: &ge;0.1% and &lt;1%;</p><p>Rare: &ge;0.01% and &lt;0.1%;</p><p>Very Rare: &lt;0.01%.</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p dir="LTR"><strong>System Organ Class </strong></p></td><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Adverse Reaction </strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p dir="LTR"><strong>Cardiac disorders </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Common</p><p dir="LTR">Rare</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Tachycardia, palpitations</p><p dir="LTR">Stress cardiomyopathy (Takotsubo cardiomyopathy)**</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p dir="LTR"><strong>Ear and labyrinth disorders </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Common</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Vertigo**, tinnitus</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p dir="LTR"><strong>Eye disorders </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Common</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Vision blurred, mydriasis</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p dir="LTR"><strong>Gastrointestinal disorders </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Very Common</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Nausea, dry mouth, constipation</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Common</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Diarrhoea, vomiting</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Rare</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Pancreatitis acute**</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p dir="LTR"><strong>General disorders and administration site conditions </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Very Common</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Fatigue</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Common</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Asthenia, chills, feeling jittery</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p dir="LTR"><strong>Immune system disorders </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td colspan="2" style="vertical-align:top"><p dir="LTR">Hypersensitivity</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Investigations </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Liver function test abnormal, weight increased, weight decreased, blood cholesterol increased</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Blood triglycerides increased, blood prolactin increased</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Metabolism and nutrition disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Decreased appetite</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Rare</p></td><td style="vertical-align:top"><p dir="LTR">Hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Musculoskeletal, connective tissue and bone disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Musculoskeletal stiffness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Nervous system disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Very Common</p></td><td style="vertical-align:top"><p dir="LTR">Headache, dizziness, somnolence</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Tremor, paraesthesia, disturbance in attention, dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Syncope, extrapyramidal disorder, dyskinesia</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Rare</p></td><td style="vertical-align:top"><p dir="LTR">Serotonin syndrome**, convulsion, dystonia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Psychiatric disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Very Common</p></td><td style="vertical-align:top"><p dir="LTR">Insomnia</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Withdrawal syndrome, anxiety, nervousness, abnormal dreams, irritability, libido decreased, anorgasmia, orgasm abnormal</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Depersonalisation, hypomania</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Rare</p></td><td style="vertical-align:top"><p dir="LTR">Mania, hallucination</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Renal and urinary disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Urinary hesitation</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Urinary retention**, proteinuria</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Reproductive system and breast disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Erectile dysfunction*, ejaculation delayed*, ejaculation disorder*, ejaculation failure*</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Sexual dysfunction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Respiratory, thoracic and mediastinal disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Yawning</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Epistaxis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Skin and subcutaneous tissue disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Very Common</p></td><td style="vertical-align:top"><p dir="LTR">Hyperhidrosis</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Rash</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Alopecia**</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Rare</p></td><td style="vertical-align:top"><p dir="LTR">Stevens-Johnson syndrome**, angioedema**, photosensitivity reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="LTR"><strong>Vascular disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Common</p></td><td style="vertical-align:top"><p dir="LTR">Blood pressure increased, hot flush</p></td></tr><tr><td style="vertical-align:top"><p dir="LTR">Uncommon</p></td><td style="vertical-align:top"><p dir="LTR">Orthostatic hypotension, peripheral coldness.</p></td></tr></tbody></table><p>&nbsp;</p><p>* Frequency is calculated based on men only.</p><p>** Adverse reaction identified during post-approval use.</p><p><strong>Adverse Reactions reported with other SNRIs </strong></p><p>Although the following are not considered adverse reactions for desvenlafaxine succinate, they are adverse reactions for other SNRIs and may also occur with desvenlafaxine succinate: gastrointestinal bleeding and severe cutaneous reactions (such as Stevens - Johnson syndrome, toxic epidermal necrolysis and/or erythema multiforme).</p><p><strong>Ischaemic Cardiac Adverse Events </strong></p><p>In clinical trials, there were uncommon reports of ischaemic cardiac adverse events including myocardial ischaemia, myocardial infarction, and coronary occlusion requiring revascularisation; these patients had multiple underlying cardiac risk factors. More patients experienced these events during Davelx treatment as compared to placebo (see PRECAUTIONS &ndash; Cardiovascular/Cerebrovascular Disease).</p><p><strong>Discontinuation Symptoms </strong></p><p>Adverse drug reactions reported in association with abrupt discontinuation, dose reduction or tapering of treatment in MDD clinical trials at a rate of 5% include: dizziness, withdrawal syndrome, nausea, headache, irritability, diarrhea, anxiety, abnormal dreams, fatigue, and hyperhidrosis. In general, discontinuation symptoms occurred more frequently with higher doses and longer duration of therapy (see METHOD OF ADMINISTRATION and PRECAUTIONS &ndash; Discontinuation Effects).</p><p><strong>Orthostatic hypotension </strong></p><p>Of the 3,292 patients in clinical trials with Prisitq, 5% of patients were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients; however, in the short-term placebo-controlled trials, there was a higher incidence of systolic orthostatic hypotension in patients &ge; 65 years of age compared to patients &lt; 65 years of age treated with Davelx.</p><p><strong>Adverse Reactions Leading to Discontinuation of Therapy </strong></p><p>The most common adverse reactions leading to discontinuation in at least 2% of the desvenlafaxine-treated patients in the short-term trials, up to 8 weeks, were: nausea (4%); dizziness and vomiting (2% each); in the long-term trial, up to 9 months, the most common was vomiting (2%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited clinical experience with desvenlafaxine overdosage in humans. In clinical trials, no cases of fatal acute overdose of desvenlafaxine succinate were reported.</p><p>Among the patients included in the major depressive disorder trials of Davelx, there were four adults who ingested doses greater than 800 mg of desvenlafaxine (4000 mg [desvenlafaxine alone], 900, 1800 mg and 5200 mg [in combination with other drugs]); all patients recovered. In addition, a patient&rsquo;s 11-month-old child accidentally ingested 600 mg of desvenlafaxine, was treated, and recovered.</p><p><strong>Management of Overdose </strong></p><p>In managing an overdose, consider the possibility of multiple drug involvement. The physician should consider contacting a poison control centre for additional information on the treatment of any overdose. For information on the management of overdose, contact the The National Pharmacovigilance and Drug Safety Centre .</p><p>Treatment should consist of those general measures employed in the management of overdosage with any SSRI/SNRI.</p><p>General supportive and symptomatic measures are recommended. Ensure an adequate airway, oxygenation and ventilation. Cardiac rhythm and vital signs must be monitored. Administration of activated charcoal may also limit drug absorption. Where there is a risk of aspiration, induction of emesis is not recommended. No specific antidotes for desvenlafaxine are known. Forced diuresis, dialysis, haemoperfusion and exchange transfusion are unlikely to be of benefit.</p><p>&nbsp;</p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">- The National Pharmacovigilance and Drug Safety Centre (NPC) :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Non-clinical studies have shown that desvenlafaxine is a selective serotonin and noradrenaline reuptake inhibitor (SNRI).</p><p><strong>Mechanism of Action</strong></p><p>Desvenlafaxine lacked significant affinity for numerous receptors, including muscarinic-cholinergic, H1-histaminergic, or 1-adrenergic receptors in vitro. Pharmacological activity at these receptors has been hypothesised to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. In the same comprehensive binding profile assay, desvenlafaxine also lacked significant affinity for various ion channels, including calcium, chloride, potassium and sodium ion channels and also lacked monoamine oxidase (MAO) inhibitory activity. Desvenlafaxine lacked significant activity in the in vitro cardiac potassium channel (hERG) assay.</p><p>In preclinical rodent models, desvenlafaxine demonstrated activity predictive of antidepressant, anxiolytic and thermoregulatory actions, and pain inhibitory properties.</p><p><strong>&nbsp;</strong></p><p><strong>Clinical Trials </strong></p><p><strong>Major Depressive Disorder </strong></p><p>The efficacy of Davelx as a treatment for depression was established in four, 8-week, randomised, double-blind, placebo-controlled, fixed-dose trials in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder (MDD). In the first study, patients received 100 mg (n = 114), 200 mg (n = 116), or 400 mg (n = 113) of Davelx once daily, or placebo (n = 118). In a second study, patients received either 200 mg (n = 121) or 400 mg (n = 124) of Davelx once daily, or placebo (n = 124). In two additional trials, patients received 50 mg (n = 150 and n = 164) or 100 mg (n = 147 and n = 158) of Davelx once daily, or placebo (n = 150 and n = 161).</p><p>Davelx showed superiority over placebo as measured by improvement in the 17-item Hamilton Rating Scale for Depression (HAM-D17) total score in four trials and, as measured by the Clinical Global Impressions Scale - Improvement (CGI-I), in three of the four trials. There was no clear evidence that doses greater than 50 mg/day conferred any additional benefit. Two other studies that treated patients with doses of 200 mg to 400 mg also showed superiority to placebo when appropriately analysed to take early drop-outs for adverse effects into account.</p><p dir="RTL">In a long-term study, adult outpatients meeting DSM-IV criteria for major depressive disorder and who responded to 12 weeks of acute treatment with Davelx were assigned randomly to the same dose (200 or 400 mg/day) they had received during acute treatment or to placebo for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a HAM-D17 total score of &le; 11 at the Day 84 evaluation. Relapse during the double-blind phase was defined as follows: (1) a HAM-D17 total score of &ge; 16 at any office visit, (2) a CGI- I score of &ge; 6 (versus day 84) at any office visit, or (3) discontinuation from the study due to unsatisfactory response. Patients receiving continued Davelx treatment experienced significantly lower relapse rates over the subsequent 26 weeks compared with those receiving placebo.</p><p>Analyses of the relationships between treatment outcome and age and treatment outcome and gender did not suggest any differential responsiveness on the basis of these patient characteristics</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The single dose pharmacokinetics of desvenlafaxine are linear and dose-proportional in a dose range of 100 to 600 mg/day. The mean terminal half-life (t1/2) is approximately 11 hours. With once-daily dosing, steady-state plasma concentrations are achieved within approximately 4-5 days. At steady state, multiple-dose accumulation of desvenlafaxine is linear and predictable from the single-dose pharmacokinetic profile.</p><p>The pharmacokinetics of desvenlafaxine have been thoroughly evaluated in women and men. There are minimal differences based on gender; data from all subjects are presented below.</p><p><strong>Absorption and Distribution </strong></p><p>Desvenlafaxine succinate is well absorbed, with an absolute oral bioavailability of 80%. Mean time to peak plasma concentrations (Tmax) is about 7.5 hours after oral administration. AUC and Cmax of 6,747 ng<strong>.</strong>hr/mL and 376 ng/mL, respectively, are predicted after a single dose of 100 mg.</p><p>Administration with food has minimal impact on drug absorption. Following administration with low, medium, and high-fat meals, increases in Cmax of approximately 16% (observed confidence interval: 107.8-125.1%; required confidence interval for bioequivalence 80-125%) were observed only following a high-fat meal. There was no statistically significant change in AUC values for any of the meals; therefore, desvenlafaxine can be taken without regard to meals.</p><p>The plasma protein binding of desvenlafaxine in vitro is low (approximately 30%) and is independent of drug concentration over the range 100-500 ng/mL. Desvenlafaxine&rsquo;s volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments.</p><p><strong>Metabolism and Excretion </strong></p><p>Approximately 45% of desvenlafaxine is excreted unchanged in urine. Desvenlafaxine is primarily metabolised by conjugation (shown to be mediated by UGT isoforms UGT1A1, UGT1A3, UGT2B4, UGT2B15, and UGT2B17 in vitro) and to a minor extent through oxidative metabolism. Approximately 19% of the administered dose is excreted as the glucuronide metabolite and &lt;5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine. In vitro studies showed that CYP3A4 is the predominant cytochrome P450 isozyme mediating the oxidative metabolism (N-demethylation) of desvenlafaxine.</p><p><strong>Special Populations </strong></p><p><strong>Elderly (&gt;65 years) </strong></p><p>In a trial of healthy subjects administered doses up to 300 mg, there was an age-dependent decrease in desvenlafaxine clearance, resulting in a 32% increase in Cmax and a 55% increase in AUC values in subjects greater than 75 years of age as compared with subjects 18 - 45 years of age. No dosage adjustment is required solely on the basis of age; however, possible reduced renal clearance of desvenlafaxine should be considered when determining dose.</p><p><strong>Paediatric</strong></p><p>Safety and effectiveness in the paediatric population have not been established.</p><p><strong>Renal Impairment </strong></p><p>The pharmacokinetics of desvenlafaxine succinate 100 mg were studied in subjects with mild (n = 9), moderate (n = 8), severe (n = 7) and end-stage renal disease (ESRD) requiring dialysis (n = 9) and in healthy, age-matched control subjects (n = 8). Elimination was significantly correlated with creatinine clearance. Total body clearance was reduced by 29% in mild, 39% in moderate, 51% in severe renal impairment, and 58% in ESRD compared to healthy subjects. This reduced clearance resulted in increases in AUCs of 42% in mild (24-hr CrCl = 50-80 mL/min), 56% in moderate (24-hr CrCl = 30-50 mL/min), 108% in severe (24-hr CrCl &lt;30 mL/min) renal impairment, and 116% in ESRD subjects.</p><p>The mean terminal half-life (t1/2) was extendeded from 11.1 hours in the control subjects to 13.5, 15.5, 17.6, and 22.8 hours in mild, moderate, severe renal impairment and ESRD subjects, respectively.</p><p>Less than 5% of the drug in the body was cleared during a standard 4-hour haemodialysis procedure. Therefore, supplemental doses should not be given to patients after dialysis. Dosage adjustment is recommended in patients with significant impairment of renal function (see METHOD OF ADMINISTRATION).</p><p><strong>Hepatic Impairment </strong></p><p>The pharmacokinetics of desvenlafaxine succinate 100 mg were studied in subjects with mild (Child-Pugh A, n = 8), moderate (Child-Pugh B, n = 8), and severe (Child-Pugh C, n = 8) hepatic impairment and in healthy subjects (n = 12).</p><p>Average AUC was increased by approximately 31% and 35% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. Average AUC values were comparable in subjects with mild hepatic impairment and healthy subjects (&lt;5% difference).</p><p>Systemic clearance (CL/F) was decreased by approximately 20% and 36% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. CL/F values were comparable in mild hepatic impairment and healthy subjects (&lt;5% difference).</p><p>The mean t1/2 changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively.</p><p><strong>Thorough QTc Trial </strong></p><p>In a thorough QTc trial with prospectively determined criteria, in healthy women, desvenlafaxine did not cause QT extendedation. Additionally, no effect on QRS interval was observed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="RTL"><strong>Genotoxicity</strong></p><p dir="RTL">Desvenlafaxine was not genotoxic in in vitro assays for bacterial gene mutation, mammalian gene mutation, chromosomal aberrations and cell transformation, or in in vivo tests for clastogenic activity in mice and rats.</p><p dir="RTL"><strong>Carcinogenicity</strong></p><p>Desvenlafaxine succinate did not increase the incidence of tumours in long-term mouse and rat carcinogenicity studies at oral doses up to 7 (mice), 14 (male rats) and 23 (female rats) times the maximal recommended human dose of 200 mg/day, on a mg/m2 basis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp; </strong><strong>List of excipients</strong></p><p>Microcrystalline cellulose</p><p>Hypromellose 2208</p><p>Magnesium stearate</p><p>Opadry II White</p><p>Red iron oxide</p><p>Yellow iron oxide</p><p>Talc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatibilities were either not assessed or not identified as part of the registration of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="RTL">Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bottle in cartons of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 MS Pharma Saudi,
Riyadh, Kingdome Saudi Arabia.
medical-ksa@mspharma.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Mar-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>